Non-functioning adenoma
At present, effective pharmacotherapy is not available for non-functioning adenomas, though some tumors may show a minimal response to bromocriptine because of the presence of some dopamine receptors. Therefore, in most patients the first choice of treatment is surgery. We prefer the transsphenoidal approach regardless of the size and shape of the tumor, because this surgery is very safe and less invasive1). We have experienced a lot of problems with transcranial surgery, especially for large pituitary adenomas. When huge adenomas are resected extensively by the transcranial route, the operative results are generally very poor. If a small amount of tumor is left after transsphenoidal surgery, we treat the patient
The number of surgical cases has been decreasing, because bromocriptine is very effective for prolactinomas. In most patients bromocriptine significantly decreases not only serum PRL levels but also tumor volume, although sensitivity to this drug differs from case to case2). In very sensitive cases, a small dose of bromocriptine can induce the normalization of serum PRL and a marked reduction in tumor size. However, in about 10% of prolactinomas this medication can hardly normalize serum PRL levels (relatively resistant cases)3). Several authors have reported extremely resistant cases which showed the exacerbation or metastases of the tumor in spite of the continuous administration of bromocriptine2).
Recently we have also experienced a case of bromocriptine resistant prolactinoma. In this patient the tumor grew gradually on serial MRIs, whereas serum PRL levels fell abruptly from 1,500ng/ml to less than 1ng/ml.
In most patients bromocriptine can control hyperprolactinemia and tumor size, but it cannot cure the disease completely. Usually, serum PRL levels rised again quickly if administration of bromocriptine is stopped. Serum PRL levels increased again to about 50% of the pre-treatment values one month after withdrawal of bromocriptine, which could sufficiently suppress hyperprolactinemia for at least one year. Therefore the patients must take this medicine for an indefinite period.
Given this background, our present policy for the treatment of prolactinomas is as follows: if hyperprolactinemia is present but a microadenoma is not detected by imaging diagnoses, we treated the patient with a small dose of bromocriptine or simly observe without any treatment. When MRI shows an enclosed microadenoma, we recommend transsphenoidal surgery because the successs rate for cure is approximately 90%. For invasive micro-or small adenomas we use bromocriptine, because we cannot estimate a high remission rate by surgery alone. If a patient gets pregnant by this pharmacotherapy, the degree of exacerbation is controllable in these small adenomas. For large prolactinomas with suprasellar extension, we adopt transsphenoidal surgery in order to reduce the tumor bulk.
The purpose of surgery is not the normalization of hyperprolactinemia but the decompression of the optic pathway and the sealing of the sellar floor. Patients with CSF rhinorrhea and/or pneumocephalus have been reported during bromocriptine treatment for large invasive prolactinomas. After surgery bromocriptine (7.5-22.5mg/day) is administered . We do not use radiation therapy for patients with prolactinoma except in cases of bromocriptine resistant tumors.
GH secreting adenoma
Although several kinds of treatment for acromegaly are available, surgery must be the first choice in most patients. The post-operative cure rate correlates with pre-operative serum GH levels, size of tumor and invasiveness. If serum GH levels are less than 50ng/ml, about 90% of the patients show remission after surgery . Since GH levels do not always correlate eith tumor size , some large adenomas are not accompanied by high GH levels. In such cases we can hardly normalize GH values in spite of the extensive removal of the tumor.
In the 1980s most investigators adopted "GH level of less than 5ng/ml" as the criteria for cure in acromegalic patients . Recently it has become much stricter, and a GH level of less than 2-3ng/ml in glucose tolerance test1) is required . Our present definition for postoperative cure is the normalization of serum GH level (<5ng/ml) and IGF-1 value (variable according to age). Somatosatin analogue (octreotide or Sandostatin) is effective in reducing serum GH levels in almost all patients and in decreasing tumor volume in 20-30% of them. However, octreotide must be injected subcutaneously three times a day or given with a microinfusion pump. Therefore, it can be used to control GH hypersecretion for a short period, such as pre-operative adjuband therapy. In most cases, a reduction of tumor size occurs within one or two week4,5). Like bromocriptine, somatostatin can only control the disease. Thus, serum GH values and tumor volume return to the original level after withdrawal of this medication.
ACTH secreting adenoma ACTH hypersecretion from the pituitary gland under hypercortisolism is called Cushing's disease. It is sometimes difficult to distinguish Cushing's disease from an ectopic ACTH secreting tumor not only by endocrinological examinations but also by imaging diagnoses.
Previously, bilateral adrenal glands were resected in patients with an indefinite cause of hypercortisolism (Nelson's syndrome).
As a rule high dose dexamethasone (8mg) suppresses cortisol hypersecretion in Cushing's 
